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Abstract
Evidence on eccrine porocarcinoma (EPC) was revised in
response to the case of a 74-year old patient, presenting
with an EPC located in the breast and initially treated with
local excision only. She was referred to our center after
loco-regional recurrence, but re-excision with
lymphadenectomy and adjuvant radiotherapy to a dose of
66 Gy failed to obtain loco-regional control.
EPC is a rare disease, occurring in 0.005-0.01% of all skin
cancers. The probability of misdiagnosis is high, especially
in case of an unusual primary site of tumour location.
Clinical and histological diagnosis encompasses a large list
of differential diagnoses. Treatment primarily consists of
surgery, with lymphadenectomy in case of unfavorable
characteristics. No evidence exists for adjuvant systemic
or loco-regional treatment.
Keywords: Eccrine Porocarcinoma (EPC); Breast cancer;
Skin cancer; Surgery; Radiotherapy; Pathology; PET-CT
Introduction
A 74-year old patient, diagnosed with an eccrine
porocarcinoma (EPC), primarily localized in the breast, was
referred to our hospital.
Two years earlier she underwent a lumpectomy for a
polypoid nodule in the right breast at her local hospital.
Histopathology revealed an eccrine carcinoma, completely
resected. As the axilla was clinically negative on palpation and
ultrasonography, no lymphadenectomy was performed.
At the time of referral, the patient had already consulted
her surgeon due to a painful rash and purple nodules in the
superior external quadrant of the right breast. The lesions
were re-resected and histopathological examination confirmed
relapse of eccrine porocarcinoma, largest diameter 45 mm.
Resection margins were free, but lymphovascular invasion was
present. Neither preoperative staging nor lymphadenectomy
had been performed. Hormonal receptors were not analysed.
Because of this disturbing histology, a mammography and
ultrasound were performed postoperatively, revealing an
enlarged lymph node in the right axilla. Fine needle aspiration
confirmed presence of metastatic carcinoma, compatible with
EPC. Postoperative computer tomography (CT) thorax
disclosed a large axillary mass, invading the pectoral muscle,
with enlarged lymph nodes higher up in the axilla (level 2).
On fluorodeoxyglucose (FDG) positron emission tomography
(PET)-CT the axillary mass was intensely FDG-avid, as were
three axillary lymph nodes, posterior to the mass (Figure 1).
On CT, two small pulmonary nodules were visible in the right
upper lobe. These lesions were not FDG-avid, but follow-up
was advised since PET is less sensitive for small lesions [1]. In
view of these findings, the patient was referred to our centre
for further investigation and treatment. An additionial bone
scan did not reveal other lesions. Magnetic resonance imaging
(MRI) excluded tumour-localization in the breast.
In multidisciplinary concertation, the tumour was
considered to be still loco-regional (making abstraction of the
pulmonary micronodules). The option of completion surgery
followed by adjuvant radiotherapy was discussed with the
patient. As she opted for maximal chances to obtain loco-
regional control, a wide resection of the residual mass was
performed in combination with axillary lymphadenectomy. All
skin nodules were resected. Dissection proved difficult
because of strong adhesion of the tumour to surrounding
tissue. Because the tumour enveloped the axillary vene it had
to be transected and extensive clipping of branches of the
axillary vein was needed. Immediate postoperative
haemorrhage required revision of the wound to obtain
haemostasis. Postoperative care was complicated due to a
wound infection, which was successfully treated with
antibiotics.
Histopathology reported an infiltrative, morphologically
high-grade tumour connected to the epidermis with partial
lobular growth architecture, compatible with the diagnosis of
EPC, ‘infiltrative subtype’, with diameter exceeding 90 mm
(Figure 2). The tumour had an obvious endophytic growth
pattern with invasion of the deep reticular dermis and subcutis
(Figures 2a-2c). Ductal differentiation was observed and the
presence of ducts and intracytoplasmic lumina (Figures 2d-2f)
was highlighted with the histochemical PAS staining and the
immunohistochemical EMA and CEA stainings. The tumour
cells showed nuclear pleomorphism and conspicuous mitotic
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activity (Figure 2e). Areas of comedo type necrosis (Figure 2d)
and lymphovascular invasion (Figure 2g) were observed. Foci
of squamous differentiation were present.
Immunohistochemistry showed tumour positivity for p63, CK5
and EMA. Estrogen and progesterone receptors and Her2Neu
were negative in the tumour. P40 stained only weakly, CK7 and
GATA 3 were negative. Margins were clear of tumour.
All lymph nodes were invaded by EPC with presence of
capsular disruption and focal invasion of the resection
margins.
A resected skin nodule also showed metastatic EPC,
invading dermis and subcutaneous fat tissue (maximum depth
4 mm) and displaying extensive lymphovascular invasion.
Because of the unfavourable characteristics (focal invasion
of the resection margins, extensive lymphovascular invasion
and invasion of the lymph nodes with capsular extension) the
patient was referred for adjuvant radiotherapy. MRI of the
axilla helped in delineating the target volume and identifying
the brachial plexus. To obtain maximal control, a dose of 66 Gy
in 33 sessions of 2 Gy was prescribed, using intensity
modulated external beam radiotherapy. After 25 sessions, a
small region of moist desquamation was observed deep in the
axillary armpit. This was successfully treated with Mepilex.
Overall, the treatment was well tolerated, and radiotherapy
could be completed without any further problems (Figure 1,
right).
Figure 1 Iconography and clinical images of the case
reported. Left above: PET-CT, after removal of the recurred
EPC, revealing an axillary location of a suspicious mass.
Right-side is the dosimetric planning of adjuvant
radiotherapy after removal of the axillary mass. Left below
is a photograph of the patient, showing in-field recurrence 3
months after removal of the axillary mass and adjuvant
radiotherapy.
Unfortunately, three months after radiotherapy, a painful
recurrence of the skin nodules was observed at the level of the
breast scar, on the right scapula and at the dorsal side of the
right upper arm (Figure 2). In order to alleviate symptoms, a
wide resection of these metastases was performed. As
expected, histopathological examination confirmed EPC
recurrence.
Figure 2 Histopathology of eccrine porocarcinoma.
Histology of an infiltrative tumour partially connected to the
epidermis (2a) (H&E, original magnification 40x). Infiltrative
growth pattern with invasion of the deep reticular dermis
and subcutis (2b and 2c) (H&E, original magnification 40x
and 100x). Note comedonecrosis (2d) (H&E, original
magnification 100x). Higher magnification reveals the
presence of atypical basaloid tumour cells with
pleomorphism and mitotic activity (2e) (H&E, original
magnification 200x). Focal clear cell change and ductal
differentiation are seen in the tumornests (2f) (H&E,
original magnification 200x). Lymphatic invasion by
neoplastic cells (2g) (H&E, original magnification 400x).
Lymph node metastasis (2h) (H&E, original magnification
40x).
Because of limited evidence for chemotherapy in a patient
already compromised by advanced age and multi-comorbidity
(including diabetes, thrombo-embolic events and obesity) it
was decided to withhold systemic therapy. When new skin
metastases appeared, the possibility of palliative radiotherapy
was proposed, but refused by the patient. It was decided to
limit further therapy to best supportive care. Six months later
the patient died from acute multi-organ failure.
Overall, 3.3 years elapsed between first resection of the
primary tumour and death. The first recurrence was observed
22.5 months after a limited resection. Following extensive
surgery and adjuvant radiotherapy for advanced loco-regional
disease, the patient survived a further 17.5 months (Table 1).
Table 1 Histologic subtypes.
Pushing subtype Polypoid with a clear lower dermal limit
Infiltrative subtype Ill-defined lower limit with malignant clusters infiltrating in the dermis and/or hypodermis
Pagetoid subtype Intra-epidermal spreading of tumour cells on the side of the main tumour, mimicking Paget disease.
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Note: Different types of histology based on tumour margin [2-21].
Prevalence
Eccrine porocarcinoma is an invasive carcinoma of the
eccrine sweat glands, with an acrosyringeal origin. Other
names were epidermotropic eccrine carcinoma, poro-
epithelioma, malignant hidroacanthoma simplex, malignant
intraepidermal eccrine poroma, malignant eccrine poroma,
malignant syringo-acanthoma and dysplastic poroma. In 1992,
Snow et al. proposed a uniform terminology, to avoid further
underreporting: the term eccrine porocarcinoma (EPC) was
suggested [2].
Benign lesions (eccrine and more rarely, apocrine poroma)
occur in up to 0.1% of primary cutaneous lesions [3], EPC
constitutes only 0.005% to 0.01% of all skin cancers [4].
Mc Lean et al. divided sweat gland carcinomas in 7
subgroups, with the classical EPC (or eccrine adenocarcinoma)
being the most prevalent [5]:
• Classic-type eccrine adenocarcinoma (or eccrine
porocarcinoma)
• Syringoid eccrine carcinoma
• Microcystic Adnexal Carcinoma
• Mucinous eccrine carcinoma
• Muco-epidermoid carcinoma
• Adenoid cystic carcinoma
• Aggressive digital papillary adenoma/adenocarcinoma
EPC can arise de novo or evolve from a benign poroma, an
evolution described to occur in one-fifth of poromas [6].
However, poroma is primarily found in regions with a high
density of eccrine sweat glands (palms or soles), whereas
porocarcinoma occurs only rarely in these regions and more
frequently on the extremities (>50%), the trunk, the head and
neck. Other locations have been described (breast, vulva,
scrotum, nail bed).
EPC occurs more often in the sixth to seventh decade of life,
with a modestly higher prevalence in women. A correlation
might exist with immuno-depression (transplant, HIV,
chemotherapy), radiation exposure and chronic radiation
dermatitis [7]. It has been described as developing in
association with extra mammary Paget’s disease [8],
sarcoidosis [9], chronic lymphocytic leukaemia [10], pernicious
anaemia [11], Hodgkin’s disease [8], nevus sebaceous [12], HIV
[13] and xeroderma pigmentosum [14].
After proliferation within the epidermis, invasion of
papillary dermis and reticular dermis follow. After invasion of
the dermal lymphatics, the tumour can spread to the lymph
nodes (described in 20% of cases), in distant solid organs (10%
of cases) or recur locally (20% of cases) [15].
Clinical Diagnosis
EPCs are not clinically distinctive and mostly described as
verrucous plaques or polypoid growths, often clinically
misdiagnosed as squamous cell carcinoma, Bowen’s disease,
seborrheic keratosis or pyogenic granuloma. The lesions can
be erythematous to violaceous in colour. Porocarcinoma has a
tendency to be more exophytic and ulcerative compared to
poroma [16] (Figure 3). Biopsy is mandatory for a correct
diagnosis.
Figure 3 Clinical aspect clinical aspect of tumour: above:
first recurrence; below: second recurrence, 3 months after
radiotherapy.
Work up
Work up should consist of an extensive medical history,
including toxic exposure, extensive clinical evaluation of the
skin and adjacent lymph node regions. CT of pelvis, abdomen
and thorax should be performed. Bone scan is useful to
exclude bone metastases.
PET-CT for porocarcinoma seems promising: in 2005 Cho
describes the case of a recurrent porocarcinoma, where FDG-
PET-CT clearly highlighted multiple FDG-avid foci over skin and
lymph nodes [17]. Histology confirmed the diagnosis. A second
FDG-PET-CT five months later revealed lesions in skin, bone,
lungs and lymph nodes. Another case was reported in 2007,
also confirming correct diagnosis of metastases using FDG-PET-
CT [18] and a similar third case was described in 2014 by
Golemi et al. [19]. The primary tumour as well as subsequent
metastases display a high glucose metabolism, which probably
explains adequate detection.
Histology
The clinical and histologic features of eccrine poroma,
porocarcinoma and related lesions are thoroughly described in
a review by Sawaya et al. [20].
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Histopathologically, the major differential diagnoses are
eccrine poroma, hidradenoma, hidradenocarcinoma,
squamous cell carcinoma and basal cell carcinoma.
Especially in superficial (shave) biopsies eccrine poroma can
be difficult to differentiate from non-invasive (in situ) EPC or
pushing subtype of EPC. However, eccrine poroma lacks
dermal invasion, significant cytologic atypia and necrosis.
Most cases of EPC are easily distinguishable from basal cell
carcinomas, however EPC must be differentiated from
infiltrating subtypes of basal cell carcinomas by the presence
of intercellular bridges and the absence of peripheral
palisading and tumour-tumour retraction artefact. Squamoid
variants of EPC may be difficult to differentiate from squamous
cell carcinoma but squamous cell carcinoma lacks ductal
structures and intracytoplasmic lumina, which can be
highlighted with the immunohistochemical EMA and CEA
staining. In this particular case, an invasive breast ductal
carcinoma can be added in the differential diagnosis, as an EPC
presenting in the axillary lymph nodes or in the breast is hard
to differentiate from a primary breast carcinoma. Histology is
complex, and misdiagnosis has been reported in up to 1/3 of
cases [21]. Based on the morphology (connection of the
tumour to the epidermis and the ductal eccrine
differentiation) and the immunohistochemistry (negativity of
CK7, ER, PR and GATA3) of the present case, the diagnosis of a
primary breast carcinoma was unlikely. Moreover, the diffuse
tumour-positivity for p63 and CK5 conflicts with a metastatic
tumour to the skin, which is typically negative for p63 and CK5
(Table 2).
Table 2 Differential diagnoses.
Clinical and histopathological differential diagnosis (DD)
Eccrine Poroma Porocarcinoma
Basal cell carcinoma Basal cell carcinoma
Seborrheic keratosis Seborrheic keratosis (clinical DD only)
Hidradenoma Hidradenoma
Pyogenic granuloma (clinical DD only) Pyogenic granuloma (clinical DD only)
Acrochordons (clinical DD only) Acrochordons (clinical DD only)
Verrucae Verrucae
Naevus (clinical DD only) Hidradenocarcinoma
Fibroma (clinical DD only) Bowen’s disease (SCC in situ)
Paget’s disease
Amelanotic melanoma (clinical DD only)
Squamous cell carcinoma
Metastasis (lung cancer, other)
Invasive ductal cell breast carcinoma
Note: Differential diagnosis of poroma and porocarcinoma, indicating which diagnoses are based on clinical findings only.
Prognostic factors
In porocarcinoma, tumour size is of no prognostic value.
Unfavourable prognostic indicators for EPC include mitotic
activity, lympho-vascular invasion and tumour thickness.
Tumours with an infiltrating rather than a “pushing” lower
border is associated with a greater risk of recurrence [22,23].
In a retrospective analysis of 24 patients, EPC was divided in
three subtypes: infiltrative, pushing and pagetoid [21].
Recurrence occurred in 35% of patients and was associated
with the histological subtypes displaying pagetoid margins
(2/2) or infiltrative margins (4/10), while none of the
“pushing” subtypes relapsed. Similar to the findings of Robson
et al.  an infiltrative tumour margin was predictive for local
recurrence [6]. No effect of the extent of resection margin was
observed (≥ 2 cm (6 pts.), <2 cm (13 pts.) or narrow margin by
modified/slow Mohs micrographic surgery (MMS) (2 pts.) were
compared), whatever the subtype. The authors suggested
narrow-margin excision for the less aggressive pushing EPC
and modified MMS for the infiltrative or pagetoid subtypes.
Treatment
After biopsy and work up, the primary treatment for both
the benign poroma and its malignant counterpart, is surgery.
Non-invasive poroma
Benign poroma should always be removed, since 20% risk
transition into its invasive counterpart [6,24]. Removal results
in a high probability of complete curation, even after simple
excision for small lesions or MMS for large or deep lesions. For
superficial lesions fulguration, cautery, excision or electro-
cauterization procedures are sufficient.
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Invasive porocarcinoma
Surgery with wide excision is the standard treatment for
non-metastatic EPC. In early stage porocarcinoma, wide
surgical excision results in a high cure rate of 70-80%.
Lymphadenectomy is advised in cases of poor prognostic
characteristics (lymphovascular invasion, infiltrative or
pagetoid tumour margin or high-grade lesions) because of its
high tendency for local recurrence (in 20% of cases), loco-
regional recurrence (20% of cases) and visceral metastasis
(10% of cases) [6,25-27]. Little evidence exists on the benefit
of adjuvant treatment, but in case of positive resection
margins, adjuvant radiotherapy seems advisable. No clear
guidelines on dose or fractionation are available.
In case of loco-regional recurrence, re-excision remains the
treatment paradigm. Radiotherapy and chemotherapy are also
options.
Metastatic disease survival can be prolonged with palliative
chemotherapy and/or radiotherapy and in case of hormonal
receptor positivity, Tamoxifen. However, outcomes are poor,
with survival varying between 5 and 24 months. An overview
on treatment options is listed in Table 3 [28-46].
Table 3 Systemic treatment.
Cyclophosphamide, bleomycine, cisplatin, 5-FU 24 pt, PR - 5-8 months Coonly [28]
Melphalan & Intra-arterial 5-FU 1 pt, CR Briscoe [29]
5-FU + radiotherapy 1 pt, PR Mitts [30]
5-FU continuous (4d 1q4) Swanson [31]
Doxorubicine, Mitomycine-C, Vincristine, 5-FU
alternating with Cisplatinum, Bleomycin (1q2)
Prolonged CR
(but serious toxicity after 9 cycli) - 16 months
Piedbois
Cyclophosphamide, vincristine, prednisone PR, 2-4 months Coonly (28)
Isotretinoin 1 pt, PR - 8wks
1 pt, no response
Roach [8]
Friedland [32]
Interferon-Alpha, Interleukin-2 1 pt, SD
1 pt, SD
Dummer [33]
Barzi [34]
Docetaxel 1 pt, PR
CR in lung, PR in breast
Plunkett [35]
Aaribi [36]
Docetaxel, topic 5-FU 1 pt, CR 2 y De Bree [37]
Paclitaxel, interferon alpha 1 pt, SD Gutermuth [38]
5-fluorouracil 1 pt, CR
1 pt, CR
Bellman [39]
Swanson [31]
5-Fluorouracil, Epirubicin, Cyclophosphamide 1 pt, SD - 17 months Mc Lean [5]
Tamoxifen 1 pt, CR 3 years
2 pt
CR - 3 years in ER/PR positive tumor
No response in ER/PR negative
Schroder [40]
Shridar [41]
Topical diphencyprone 6% 1 pt, CR (skin lesions) 6 months Kutty [42]
Radiotherapy IMRT 30 × 2 Gy - DFS 10 months
--
1 pt, LC 18 months
1 pt, Cyberknife, 10 × 5 Gy, CR 1 year
Zeidan [43]
Mertens [44]
Grizzard [45]
Fujimura [46]
Abbreviations: CR: Complete Remission; PR: Partial Remission; SD: Stable Disease; LC: Local Control; Pt: Patient; ER: Estrogen Receptor; PR: Progesterone
Receptor
Discussion
In this patient, the initial clinical presentation of a superficial
polypoid breast nodule might have suggested a non-breast
tumour. Unfortunately, no images of the primary lesion exist.
No detailed information on the histopathology of the
excisional biopsy could be found. Information on prognostic
characteristics, including infiltrative spread, presence of
lymphovascular invasion and mitotic activity, could have
helped differentiating between a conservative and a more
invasive approach. A postoperative work-up with CT-thorax,
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CT-abdomen and bone scan at initial diagnosis would have
been justified, completed with PET-CT in case of doubt or
suspicion for metastases. Even though initial clinical axillary
examination and ultrasonography were negative,
lymphadenectomy is advisable in case of unfavourable tumour
characteristics.
No evidence exists on adjuvant treatment after surgery.
However, radiotherapy had been an option in case of positive
resection margins or extensive lympho-vascular invasion.
At the moment of recurrence, resection of the superficial
lesions was performed without preoperative staging,
overlooking a large axillary mass and necessitating a second
surgical intervention in a patient, already compromised by age
and co-morbidity. As postoperative staging revealed residual
tumor, and as patient and family choose for maximal loco-
regional control, salvage treatment with debulking and
adjuvant radiotherapy were performed. Because of the
proximity of the brachial plexus a normofractionated schedule
was opted for. Evidence on hypofractionation for EPC is
lacking; in retrospect however, a lower number of treatment
sessions to reduce the burden of transportation for patient
and family might have been an acceptable alternative. Even in
the proximity of the brachial plexus, a schedule consisting of
20 fractions of 2.67 Gy or 5 fractions of 6 Gy may have been
safe, as these results respectively in an EQD2 of 63.6 Gy and
64.3 Gy when applying an α/β of 1.5 Gy. As yet, no evidence
exists on the benefit of hypofractionation for EPC.
No systemic therapy was added: as hormone receptors were
negative, no benefit was expected from adding tamoxifen. At
the time of second relapse, the performance status of this
patient, already compromised by morbid obesity and diabetes,
did not permit administration of docetaxel or other
chemotherapy.
Conclusion
Breast locations of EPC, an uncommon skin cancer, are
misleading and could cause surgeons to underestimate the
risks of lymphatic and dermal spread of this type of carcinoma,
which behaves quite differently from breast carcinoma.
Various appearances and a broad range of differential
diagnoses are prone to misdiagnosis. If complete surgical
excision is possible in early stage disease, loco-regional control
can be accomplished in 70-80% of cases. Lymphadenectomy is
recommended in case of unfavourable prognostic
characteristics. Evidence on the benefit of adjuvant treatment
is lacking. However, there may be a role for radiotherapy in
case of positive resection margins or extensive lymphovascular
spread.
Though prolonged disease stabilization in metastatic disease
is reported with poly-chemotherapy, it comes at the cost of
severe toxicity [27]. Reports exist on complete or partial
remission following the use of docetaxel or isotretinoin. In
ER/PR positive tumours, use of tamoxifen may stabilize
disease.
In brief, the presented case is an example of an apparently
innocuous breast nodule, where initial underestimation of the
aggressiveness of EPC histology may have compromised the
final outcome.
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